Search

Your search keyword '"VON HAEHLING, Stephan"' showing total 1,823 results
Start Over Author "VON HAEHLING, Stephan"
1,823 results on '"VON HAEHLING, Stephan"'

4. Kidney function in cachexia and sarcopenia: Facts and numbers.

Author

Okamura, Masatsugu, Konishi, Masaaki, Butler, Javed, von Haehling, Stephan, Anker, Stefan, and Kalantar-Zadeh, Kamyar

Subjects
Cachexia, Chronic kidney disease, Cystatin C, Protein-energy wasting, Sarcopenia, Humans, Cachexia, Cystatin C, Sarcopenia, Creatinine, Renal Insufficiency, Chronic, Kidney
Abstract

Cachexia, in the form of unintentional weight loss >5% in 12 months or less, and secondary sarcopenia in the form of muscle wasting are serious conditions that affect clinical outcomes. A chronic disease state such as chronic kidney disease (CKD) often contributes to these wasting disorders. The purpose of this review is to summarize the prevalence of cachexia and sarcopenia, their relationship with kidney function, and indicators for evaluating kidney function in patients with CKD. It is estimated that approximately half of all persons with CKD will develop cachexia with an estimated annual mortality rate of 20%, but few studies have been conducted on cachexia in CKD. Hence, the true prevalence of cachexia in CKD and its effects on kidney function and patient outcomes remain unclear. Some studies have highlighted the concept of protein-energy wasting (PEW) which usually include sarcopenia and cachexia. Several studies have examined kidney function and CKD progression in patients with sarcopenia. Most studies use serum creatinine levels to estimate kidney function. However, creatinine may be influenced by muscle mass, and creatinine-based glomerular filtration rate may overestimate kidney function in patients with reduced muscle mass or muscle wasting. Cystatin C, which is least affected by muscle mass, has been used in some studies, and creatinine-to-cystatin-C ratio has emerged as an important prognostic marker. A previous study incorporating 428 320 participants reported that participants with CKD and sarcopenia had a 33% higher hazard of mortality compared with those without (7% to 66%, P = 0.011), and that those with sarcopenia were twice as likely to develop end-stage kidney disease (hazard ratio: 1.98; 1.45 to 2.70, P

Published
2023

6. The prevalence and impact of sarcopenia in older cardiac patients undergoing inpatient cardiac rehabilitation – results from a prospective, observational cohort pre-study

Author

Steinmetz, Carolin, Krause, Laura, Sulejmanovic, Samra, Kaumkötter, Sabrina, Mengden, Thomas, Grefe, Clemens, Knoglinger, Ernst, Reiss, Nils, Brixius, Klara, Bjarnason-Wehrens, Birna, Schmidt, Thomas, von Haehling, Stephan, Sadlonova, Monika, von Arnim, Christine A. F., and Heinemann, Stephanie

Published
2024
Full Text
View/download PDF

7. Association of an impaired GH-IGF-I axis with cardiac wasting in patients with advanced cancer

Author

Fröhlich, Ann-Kathrin, Porthun, Jan, Talha, Khawaja M., Lena, Alessia, Hadzibegovic, Sara, Wilkenshoff, Ursula, Sonntag, Frederike, Nikolski, Anja, Ramer, Luisa Valentina, Zeller, Tanja, Keller, Ulrich, Bullinger, Lars, Anker, Stefan D., Haverkamp, Wilhelm, von Haehling, Stephan, Doehner, Wolfram, Rauch, Ursula, Skurk, Carsten, Cleland, John G. F., Butler, Javed, Coats, Andrew J. S., Landmesser, Ulf, Karakas, Mahir, and Anker, Markus S.

Published
2024
Full Text
View/download PDF

10. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

Author

Penson, Peter E, Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P, Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P, Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, GB John, von Haehling, Stephan, Banach, Maciej, and International Lipid Expert Panel (ILEP)

Subjects
International Lipid Expert Panel, Muscles, Humans, Muscular Diseases, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Nocebo Effect, Drucebo effect, Nocebo effect, SAMS, Statin intolerance, Pain Research, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, 7.3 Management and decision making, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Physiology, Clinical Sciences, Human Movement and Sports Sciences
Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.

Published
2022

11. Predictors of lower exercise capacity in patients with cancer

Author

Evertz, Ruben, Diehl, Christine, Gödde, Katharina, Valentova, Miroslava, Garfias-Veitl, Tania, Overbeck, Tobias R., Braulke, Friederike, Lena, Alessia, Hadzibegovic, Sara, Bleckmann, Annalen, Keller, Ulrich, Landmesser, Ulf, König, Alexander O., Hasenfuss, Gerd, Schuster, Andreas, Anker, Markus S., and von Haehling, Stephan

Published
2023
Full Text
View/download PDF

18. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Author

de Boer, Rudolf, Hulot, Jean-Sébastien, Tocchetti, Carlo, Aboumsallem, Joseph, Ameri, Pietro, Anker, Stefan, Bauersachs, Johann, Bertero, Edoardo, Coats, Andrew, Čelutkienė, Jelena, Chioncel, Ovidiu, Dodion, Pierre, Eschenhagen, Thomas, Farmakis, Dimitrios, Bayes-Genis, Antoni, Jäger, Dirk, Jankowska, Ewa, Kitsis, Richard, Konety, Suma, Larkin, James, Lehmann, Lorenz, Lenihan, Daniel, Maack, Christoph, Moslehi, Javid, Müller, Oliver, Nowak-Sliwinska, Patrycja, Piepoli, Massimo, Ponikowski, Piotr, Pudil, Radek, Rainer, Peter, Ruschitzka, Frank, Sawyer, Douglas, Seferovic, Petar, Suter, Thomas, Thum, Thomas, van der Meer, Peter, Van Laake, Linda, von Haehling, Stephan, Heymans, Stephane, Lyon, Alexander, and Backs, Johannes

Subjects
Angiogenesis, Cancer, Cardio-oncology, Cardiotoxicity, Clonal haematopoiesis, Extracellular matrix, Heart failure, Inflammation, Metabolism, Comorbidity, Heart Failure, Humans, Inflammation, Neoplasms, Risk Factors
Abstract

The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time.

Published
2020

19. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Author

Lyon, Alexander, Dent, Susan, Stanway, Susannah, Earl, Helena, Brezden-Masley, Christine, Cohen-Solal, Alain, Tocchetti, Carlo, Moslehi, Javid, Groarke, John, Bergler-Klein, Jutta, Khoo, Vincent, Tan, Li, Anker, Markus, von Haehling, Stephan, Maack, Christoph, Pudil, Radek, Barac, Ana, Thavendiranathan, Paaladinesh, Ky, Bonnie, Neilan, Tomas, Belenkov, Yury, Rosen, Stuart, Iakobishvili, Zaza, Sverdlov, Aaron, Hajjar, Ludhmila, Macedo, Ariane, Manisty, Charlotte, Ciardiello, Fortunato, Farmakis, Dimitrios, de Boer, Rudolf, Skouri, Hadi, Suter, Thomas, Cardinale, Daniela, Witteles, Ronald, Fradley, Michael, Herrmann, Joerg, Cornell, Robert, Wechelaker, Ashutosh, Mauro, Michael, Milojkovic, Dragana, de Lavallade, Hugues, Ruschitzka, Frank, Coats, Andrew, Seferovic, Petar, Chioncel, Ovidiu, Thum, Thomas, Bauersachs, Johann, Andres, M, Wright, David, López-Fernández, Teresa, Plummer, Chris, and Lenihan, Daniel

Subjects
Cardio-oncology, Cardiotoxicity, Heart failure, Risk factors, Risk prediction, Aged, Androgen Antagonists, Antineoplastic Agents, Cardiovascular Diseases, Female, Heart Disease Risk Factors, Humans, Male, Middle Aged, Neoplasms, Risk Assessment, Risk Factors
Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Published
2020

20. Defining terms commonly used in sarcopenia research: a glossary proposed by the Global Leadership in Sarcopenia (GLIS) Steering Committee

Author

Cawthon, Peggy M., Visser, Marjolein, Arai, Hidenori, Ávila-Funes, José A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen, Bruyère, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Kirk, Ben, Landi, Francesco, Sayer, Avan A., Von Haehling, Stephan, Woo, Jean, and Cruz-Jentoft, Alfonso J.

Published
2022
Full Text
View/download PDF

23. Hypokalaemia and outcomes in older patients hospitalized for heart failure.

Author

Valentova, Miroslava, Patel, Samir, Lam, Phillip H, Faselis, Charles, Arundel, Cherinne, Fonarow, Gregg C, Cheng, Yan, Allman, Richard M, von Haehling, Stephan, Anker, Stefan D, and Ahmed, Ali

Subjects
Heart failure, Hospitalization, Mortality, Potassium, Propensity score, Cardiorespiratory Medicine and Haematology
Abstract

AimsHypokalaemia is a risk factor for ventricular arrhythmias and sudden death in ambulatory patients with chronic heart failure (HF). The objective of this study was to examine the association between hypokalaemia and outcomes in hospitalized patients with decompensated HF in whom sudden death is less common.Methods and resultsOf the 5881 hospitalized patients with HF, 1052 had consistent hypokalaemia (both admission and discharge serum potassium

Published
2020

24. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

26. Positionspapier Herzinsuffizienz und Diabetes

Author

Schütt, Katharina, Aberle, Jens, Bauersachs, Johann, Birkenfeld, Andreas, Frantz, Stefan, Ganz, Manfred, Jacob, Stephan, Kellerer, Monika, Leschke, Matthias, Liebetrau, Christoph, Marx, Nikolaus, Müller-Wieland, Dirk, Raake, Philip, Schulze, Paul Christian, Tschöpe, Diethelm, von Haehling, Stephan, Zelniker, Thomas A., and Forst, Thomas

Published
2022
Full Text
View/download PDF

29. 2024 update in heart failure

Author

Beghini, Alberto, primary, Sammartino, Antonio Maria, additional, Papp, Zoltán, additional, von Haehling, Stephan, additional, Biegus, Jan, additional, Ponikowski, Piotr, additional, Adamo, Marianna, additional, Falco, Luigi, additional, Lombardi, Carlo Mario, additional, Pagnesi, Matteo, additional, Savarese, Gianluigi, additional, Metra, Marco, additional, and Tomasoni, Daniela, additional

Published
2024
Full Text
View/download PDF

33. Sarcopenia: A Time for Action. An SCWD Position Paper.

Author

Bauer, Juergen, Morley, John E, Schols, Annemie MWJ, Ferrucci, Luigi, Cruz-Jentoft, Alfonso J, Dent, Elsa, Baracos, Vickie E, Crawford, Jeffrey A, Doehner, Wolfram, Heymsfield, Steven B, Jatoi, Aminah, Kalantar-Zadeh, Kamyar, Lainscak, Mitja, Landi, Francesco, Laviano, Alessandro, Mancuso, Michelangelo, Muscaritoli, Maurizio, Prado, Carla M, Strasser, Florian, von Haehling, Stephan, Coats, Andrew JS, and Anker, Stefan D

Subjects
Cachexia, Geriatric assessment, Muscle, Muscle strength, Sarcopenia, Skeletal
Abstract

The term sarcopenia was introduced in 1988. The original definition was a "muscle loss" of the appendicular muscle mass in the older people as measured by dual energy x-ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC-F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease-related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age-related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age-related and disease-related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life-long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.

Published
2019

37. Skeletal muscle derived Musclin protects the heart during pathological overload

Author

Szaroszyk, Malgorzata, Kattih, Badder, Martin-Garrido, Abel, Trogisch, Felix A., Dittrich, Gesine M., Grund, Andrea, Abouissa, Aya, Derlin, Katja, Meier, Martin, Holler, Tim, Korf-Klingebiel, Mortimer, Völker, Katharina, Garfias Macedo, Tania, Pablo Tortola, Cristina, Boschmann, Michael, Huang, Nora, Froese, Natali, Zwadlo, Carolin, Malek Mohammadi, Mona, Luo, Xiaojing, Wagner, Michael, Cordero, Julio, Geffers, Robert, Batkai, Sandor, Thum, Thomas, Bork, Nadja, Nikolaev, Viacheslav O., Müller, Oliver J., Katus, Hugo A., El-Armouche, Ali, Kraft, Theresia, Springer, Jochen, Dobreva, Gergana, Wollert, Kai C., Fielitz, Jens, von Haehling, Stephan, Kuhn, Michaela, Bauersachs, Johann, and Heineke, Joerg

Published
2022
Full Text
View/download PDF

38. Nutritional strategies for improving sarcopenia outcomes in older adults: A narrative review.

Author

Goes‐Santos, Beatriz R., Carson, Brian P., da Fonseca, Guilherme Wesley Peixoto, and von Haehling, Stephan

Subjects
MUSCLE mass, MUSCLE proteins, PROTEOLYSIS, OLDER people, PROTEIN synthesis, SARCOPENIA
Abstract

Sarcopenia is characterized by a decline in muscle strength, generalized loss of skeletal muscle mass, and impaired physical performance, which are common outcomes used to screen, diagnose, and determine severity of sarcopenia in older adults. These outcomes are associated with poor quality of life, increased risk of falls, hospitalization, and mortality in this population. The development of sarcopenia is underpinned by aging, but other factors can lead to sarcopenia, such as chronic diseases, physical inactivity, inadequate dietary energy intake, and reduced protein intake (nutrition‐related sarcopenia), leading to an imbalance between muscle protein synthesis and muscle protein breakdown. Protein digestion and absorption are also modified with age, as well as the reduced capacity of metabolizing protein, hindering older adults from achieving ideal protein consumption (i.e., 1–1.5 g/kg/day). Nutritional supplement strategies, like animal (i.e., whey protein) and plant‐based protein, leucine, and creatine have been shown to play a significant role in improving outcomes related to sarcopenia. However, the impact of other supplements (e.g., branched‐chain amino acids, isolated amino acids, and omega‐3) on sarcopenia and related outcomes remain unclear. This narrative review will discuss the evidence of the impact of these nutritional strategies on sarcopenia outcomes in older adults. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. The Conceptual Definition of Sarcopenia : Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS)

Author

Kirk, Ben, Cawthon, Peggy M., Arai, Hidenori, Avila-Funes, Jose A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen F., Bruyere, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Landi, Francesco, Reginster, Jean-Yves, Sayer, Avan A., Visser, Marjolein, von Haehling, Stephan, Woo, Jean, Cruz-Jentoft, Alfonso J., Kirk, Ben, Cawthon, Peggy M., Arai, Hidenori, Avila-Funes, Jose A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen F., Bruyere, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Landi, Francesco, Reginster, Jean-Yves, Sayer, Avan A., Visser, Marjolein, von Haehling, Stephan, Woo, Jean, and Cruz-Jentoft, Alfonso J.

Abstract

Importance Sarcopenia, the age-related loss of muscle mass and strength/function, is an important clinical condition. However, no international consensus on the definition exists. Objective The Global Leadership Initiative in Sarcopenia (GLIS) aimed to address this by establishing the global conceptual definition of sarcopenia. Design The GLIS steering committee was formed in 2019-21 with representatives from all relevant scientific societies worldwide. During this time, the steering committee developed a set of statements on the topic and invited members from these societies to participate in a two-phase International Delphi Study. Between 2022 and 2023, participants ranked their agreement with a set of statements using an online survey tool (SurveyMonkey). Statements were categorised based on predefined thresholds: strong agreement (>80%), moderate agreement (70-80%) and low agreement (<70%). Statements with strong agreement were accepted, statements with low agreement were rejected and those with moderate agreement were reintroduced until consensus was reached. Results 107 participants (mean age: 54 +/- 12 years [1 missing age], 64% men) from 29 countries across 7 continents/regions completed the Delphi survey. Twenty statements were found to have a strong agreement. These included; 6 statements on 'general aspects of sarcopenia' (strongest agreement: the prevalence of sarcopenia increases with age (98.3%)), 3 statements on 'components of sarcopenia' (muscle mass (89.4%), muscle strength (93.1%) and muscle-specific strength (80.8%) should all be a part of the conceptual definition of sarcopenia)) and 11 statements on 'outcomes of sarcopenia' (strongest agreement: sarcopenia increases the risk of impaired physical performance (97.9%)). A key finding of the Delphi survey was that muscle mass, muscle strength and muscle-specific strength were all accepted as 'components of sarcopenia', whereas impaired physical performance was accepted as an 'outcome' rather t

Published
2024
Full Text
View/download PDF

46. An executive summary on the Global conceptual definition of Sarcopenia.

Author

Kirk, Ben, Cawthon, Peggy M., Arai, Hidenori, Ávila-Funes, José A., Barazzoni, Rocco, Bhasin, Shalender, Binder, Ellen F., Bruyère, Olivier, Cederholm, Tommy, Chen, Liang-Kung, Cooper, Cyrus, Duque, Gustavo, Fielding, Roger A., Guralnik, Jack, Kiel, Douglas P., Landi, Francesco, Reginster, Jean-Yves, Sayer, Avan A., Visser, Marjolein, and von Haehling, Stephan

Published
2024
Full Text
View/download PDF

47. Mortality and morbidity 1 year after stopping a remote patient management intervention: extended follow-up results from the telemedical interventional management in patients with heart failure II (TIM-HF2) randomised trial

Author

Koehler, Friedrich, Koehler, Kerstin, Prescher, Sandra, Kirwan, Bridget-Anne, Wegscheider, Karl, Vettorazzi, Eik, Lezius, Susanne, Winkler, Sebastian, Moeller, Volker, Fiss, Gunnar, Schleder, Judith, Koehler, Magdalena, Zugck, Christian, Störk, Stefan, Butter, Christian, Prondzinsky, Roland, Spethmann, Sebastian, Angermann, Christiane, Stangl, Verena, Halle, Martin, von Haehling, Stephan, Dreger, Henryk, Stangl, Karl, Deckwart, Oliver, and Anker, Stefan D

Published
2020
Full Text
View/download PDF

50. Increased Expression of Proinflammatory Genes in Peripheral Blood Cells Is Associated with Cardiac Cachexia in Patients with Heart Failure with Reduced Ejection Fraction

Author

Sandek, Anja, primary, Gertler, Christoph, additional, Valentova, Miroslava, additional, Jauert, Nadja, additional, Wallbach, Manuel, additional, Doehner, Wolfram, additional, von Haehling, Stephan, additional, Anker, Stefan D., additional, Fielitz, Jens, additional, and Volk, Hans-Dieter, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results